We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Eli Lilly (LLY) Stock Slides as Market Rises: Facts to Know Before You Trade
Read MoreHide Full Article
In the latest trading session, Eli Lilly (LLY - Free Report) closed at $1,200.06, marking a -1.14% move from the previous day. The stock fell short of the S&P 500, which registered a gain of 0.72% for the day. Meanwhile, the Dow experienced a rise of 0.3%, and the technology-dominated Nasdaq saw an increase of 1.12%.
Shares of the drugmaker have appreciated by 7.29% over the course of the past month, underperforming the Medical sector's gain of 12.48%, and outperforming the S&P 500's loss of 0.9%.
The upcoming earnings release of Eli Lilly will be of great interest to investors. The company's upcoming EPS is projected at $8.98, signifying a 42.31% increase compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $20.28 billion, indicating a 30.34% increase compared to the same quarter of the previous year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $35.6 per share and revenue of $85.73 billion, which would represent changes of +47.05% and +31.53%, respectively, from the prior year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Eli Lilly. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, there's been a 0.18% fall in the Zacks Consensus EPS estimate. Right now, Eli Lilly possesses a Zacks Rank of #3 (Hold).
In terms of valuation, Eli Lilly is currently trading at a Forward P/E ratio of 34.1. This indicates a premium in contrast to its industry's Forward P/E of 16.26.
Meanwhile, LLY's PEG ratio is currently 1.51. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Large Cap Pharmaceuticals industry had an average PEG ratio of 2.73 as trading concluded yesterday.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 107, this industry ranks in the top 44% of all industries, numbering over 250.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Eli Lilly (LLY) Stock Slides as Market Rises: Facts to Know Before You Trade
In the latest trading session, Eli Lilly (LLY - Free Report) closed at $1,200.06, marking a -1.14% move from the previous day. The stock fell short of the S&P 500, which registered a gain of 0.72% for the day. Meanwhile, the Dow experienced a rise of 0.3%, and the technology-dominated Nasdaq saw an increase of 1.12%.
Shares of the drugmaker have appreciated by 7.29% over the course of the past month, underperforming the Medical sector's gain of 12.48%, and outperforming the S&P 500's loss of 0.9%.
The upcoming earnings release of Eli Lilly will be of great interest to investors. The company's upcoming EPS is projected at $8.98, signifying a 42.31% increase compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $20.28 billion, indicating a 30.34% increase compared to the same quarter of the previous year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $35.6 per share and revenue of $85.73 billion, which would represent changes of +47.05% and +31.53%, respectively, from the prior year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Eli Lilly. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, there's been a 0.18% fall in the Zacks Consensus EPS estimate. Right now, Eli Lilly possesses a Zacks Rank of #3 (Hold).
In terms of valuation, Eli Lilly is currently trading at a Forward P/E ratio of 34.1. This indicates a premium in contrast to its industry's Forward P/E of 16.26.
Meanwhile, LLY's PEG ratio is currently 1.51. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Large Cap Pharmaceuticals industry had an average PEG ratio of 2.73 as trading concluded yesterday.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 107, this industry ranks in the top 44% of all industries, numbering over 250.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.